Circulating Tumor HPV DNA May Aid Risk Assessment With Oropharyngeal Cancer

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 13, 2026.

via HealthDay

MONDAY, April 13, 2026 -- A blood test for circulating tumor human papillomavirus DNA (ctHPVDNA) may improve risk assessment in patients undergoing surgery for HPV-related oropharyngeal cancer, according to a study published online April 2 in JAMA Otolaryngology-Head & Neck Surgery.

Jack L. Birkenbeuel, M.D., from The Ohio State University in Columbus, and colleagues assessed clinicopathologic variables associated with ctHPVDNA before and after surgery. The analysis included 104 patients with HPV-mediated oropharyngeal squamous cell carcinoma treated with upfront surgery.

The researchers found that higher estimated glomerular filtration rate (rate ratio [RR], 1.05) and higher pathologic N stage (RR, 12.30) were independently associated with higher preoperative ctHPVDNA levels. Perineural invasion (PNI; RR, 0.23) and pathologic extranodal extension (pENE; RR, 0.11) were associated with lower ctHPVDNA levels. One in five patients (20.2 percent) had detectable postoperative ctHPVDNA, which was associated with more than four positive lymph nodes (odds ratio [OR], 4.86), higher preoperative ctHPVDNA levels (OR, 1.17), PNI (OR, 2.95), and pENE (OR, 3.38). Three of 15 patients (20.0 percent) with detectable postoperative ctHPVDNA experienced recurrence versus eight of 59 patients (13.6 percent) with undetectable ctHPVDNA. Four locoregional recurrences occurred in patients with undetectable postoperative ctHPVDNA who declined guideline-concordant adjuvant therapy.

"We found that the pretreatment ctDNA levels are influenced by tumor biology and kidney function," coauthor Catherine Haring, M.D., also from The Ohio State University, said in a statement. "Postoperative ctDNA reflects both residual cancer and baseline tumor DNA levels. This means the test needs to be interpreted in context. A positive result after surgery may indicate higher risk, but a negative result does not always mean a patient is in the clear."

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-14 02:09

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords